| Bioactivity | Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease[1]. | ||||||||||||
| In Vivo | Budipine (s.c., 30 μg/24 h, 11 days) is a substrate of P-glycoprotein (P-gp) and is actively transported out of the brain through the blood–brain barrier back into the blood plasma[1]. Animal Model: | ||||||||||||
| Name | Budipine | ||||||||||||
| CAS | 57982-78-2 | ||||||||||||
| Formula | C21H27N | ||||||||||||
| Molar Mass | 293.45 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Manfred Uhr, et al. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci Lett. 2005 Jul 22-29;383(1-2):73-6. |